Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles
Drug Research · 01.03.2026 · 76 (02/03) · 99-101
DOI: 10.1055/a-2769-1965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, erschienen am 01.03.2026. Verfasst von Pranay Renukuntla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, 500007, Hyderabad, India. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Proto-Oncogene Proteins c-abl, Metabolome. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
ABL kinase inhibitors have transformed the clinical management of chronic myelogenous leukemia; yet, the metabolic consequences of their use remain largely unexplored. In the current study, using K562 cell lines, the metabolic impact of five ABL kinase inhibitors, such as imatinib, dasatinib, nilotinib, ponatinib, and axitinib, was studied. Comparative metabolic profiling revealed both common and inhibitor-specific metabolic alterations. Pathway enrichment analysis identified significant downregulation in starch and sucrose metabolism, nucleotide sugar metabolism and sphingolipid metabolism. These results offered insights to guide the development of treatment strategies for overcoming the drug resistance in chronic myelogenous leukemia as well as managing the associated toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, 500007, Hyderabad, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India.
- Molecular Medicine and Therapeutics Laboratory, CPMB, Osmania University, 500007, Hyderabad, India.
ORCID-Profile: Pranay Renukuntla, Jagadeshwar Reddy Thota
Zitieren
APA
Renukuntla, P., Mullaguri, S. C., Presingu, D., Kancha, R. K., & Thota, J. R. (2026). Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles. Drug Research, 76(02/03), 99-101. https://doi.org/10.1055/a-2769-1965
Vancouver
Renukuntla P, Mullaguri SC, Presingu D, Kancha RK, Thota JR. Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles. Drug Research. 2026;76(02/03):99-101. doi:10.1055/a-2769-1965
BibTeX
@article{Renukuntla2026,
author = {Renukuntla, Pranay and Mullaguri, Sai Charitha and Presingu, Divya and Kancha, Rama Krishna and Thota, Jagadeshwar Reddy},
title = {Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles},
journal = {Drug Research},
year = {2026},
volume = {76},
number = {02/03},
pages = {99--101},
doi = {10.1055/a-2769-1965}
}
EUVIMED